• 24 October, 2026

Have a look at AstraZeneca's development pipeline

January 31, 2013 | Thursday | Company results | By BioSpectrum Bureau

2012 was a bad year for AstraZeneca - Revenue declined 15% to $27,973 mn

2012 was a bad year for AstraZeneca - Revenue declined 15% to $27,973 mn

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Most Read

Survey Box

Is Asia Pacific region racing towards greener & sustainable pharma?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls